Autologous cell suspension grafting using ReCell in vitiligo and piebaldism patients: a randomized controlled study on the recipient site preparation - ReCell in vitiligo and piebaldism: recipient site preparation

Academisch Medisch Centrum0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•Patients with, segmental vitiligo or piebaldism under medical treatment at the Netherlands Institute for Pigment Disorders
•Patient is willing and able to give written informed consent
•Segmental vitiligo stable since 12 months without systemic therapy or 12 months without topical therapy as defined by the absence of new lesions and/or enlargement of existing lesions.
•At least four depigmented lesions on the proximal extremities or trunk larger than 3x3 cm or one depigmented lesion on the proximal extremities or trunk of at least 12x3 cm

•UV therapy or systemic immunosuppressive treatment during the last 12 months
•Local treatment of vitiligo during the last 12 months
•Vitiligo lesions with follicular or non-follicular repigmentations
•Skin type I
•Recurrent HSV skin infections
•Hypertrophic scars
•Cardial insufficiency
•Patients with a history of hypersensitivity to (UVB or UVA) light and/or allergy to local anaesthesia.
•Patients who are pregnant or breast-feeding
•Patients not competent to understand what the procedures involved
•Patients with a personal history of melanoma or non-melanoma skin cancer
•Patients with atypical nevi
•Known allergy to clarithromycin

发起方